Dataset Information


The Inhibition of Wnt Restrain KRASG12V-Driven Metastasis in Non-Small-Cell Lung Cancer.

ABSTRACT: The KRAS mutations have been an obstacle to identify therapeutic targets in cancer treatment. In this work, we clarified the distinct metastasis pattern of non-small-cell lung carcinoma (NSCLC) induced by KRASG12V/KRASG12D mutations and inhibited the KRASG12V mediated metastasis by Wnt inhibitor. First, we found that KRASG12V induced more aggressive phenotype in vitro and in vivo experiments. The Gene Set Enrichment Analysis (GSEA) results of H838 KRASG12V cells showed a significant negative correlation with RhoA-related signaling. Following this clue, we observed KRASG12D induced higher activation of RhoA and suppressed activation of Wnt/?-catenin in H838KRASG12D cells. The restored activation of Wnt/?-catenin in H838KRASG12D cells could be detected when expression with a dominant-negative mutant of RhoA or treatment with RhoA inhibitor. Furthermore, the Wnt inhibitor abolished the KRASG12V-induced migration. We elucidated the importance of the axis of RhoA/Wnt in regulatory NSCLC metastasis driven by KRAS mutations. Our data indicate that KRASG12V driven NSCLC metastasis is Wnt-dependent and the mechanisms of NSCLC metastasis induced by KRASG12V/KRASG12D is distinct.


PROVIDER: S-EPMC7226522 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2011-01-01 | S-EPMC3083778 | BioStudies
2020-01-01 | S-EPMC6943152 | BioStudies
1000-01-01 | S-EPMC6345925 | BioStudies
2014-01-01 | S-EPMC4255233 | BioStudies
2020-01-01 | S-EPMC6954322 | BioStudies
2017-01-01 | S-EPMC5352098 | BioStudies
1000-01-01 | S-EPMC3189908 | BioStudies
2019-01-01 | S-EPMC6529773 | BioStudies
2017-01-01 | S-EPMC5514503 | BioStudies
2020-01-01 | S-EPMC7256677 | BioStudies